# The burden of antimicrobial resistance (AMR) in Latvia

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **300 lives** have been lost each year since 1990 in Latvia due to AMR.

- In 2021, there were an estimated **244 UI (205-283)** deaths attributable to AMR and **1,130 UI (945-1,320)** deaths associated with AMR in this location.

- The largest number of deaths associated with AMR in 2021 occurred among those aged **70+** in the country.

- Among the most deadly pathogen-drug combinations in 2021 were *Staphylococcus aureus* resistant to methicillin, *Pseudomonas aeruginosa* resistant to carbapenems and *Acinetobacter baumannii* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021

- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.

- At the 2024 United Nations General Assembly high level meeting on antimicrobial resistance, country members agreed to aim for a **10% reduction** compared to 2019 baseline **(from 4.95 to 4.45 million)** in the global number of deaths associated with AMR by 2030. But our forecast indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Latvia, a 10% reduction means to decrease the number of deaths associated with AMR to **1,070**, but currently the trend for this country could reach up to **1,100 UI [897-1,350]** AMR-associated deaths in 2030.

AMR in Latvia

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.

- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.

- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.

- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Latvia between 1990 and 2019.

- To look at these and more visualization interactively visit Measuring Infectious Causes and Resistance Outcomes for Burden Estimation (MICROBE)

- In **Latvia** in 2021, there were an estimated **244 UI (205-283)** deaths attributable to AMR and **1,130 UI (945-1,320)** deaths associated with AMR. Here *"attributable deaths"* are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. *"Associated deaths"* are considered to be those that would not have occurred had the infections been prevented entirely.

- Across 204 countries, **Latvia has the 36th lowest** age-standardized mortality rate associated with AMR in 2021.

- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

Overall susceptible and resistant		Associated		Attributable	
Staphylococcus aureus 517 UI (456-577)	↑	Escherichia coli 293 UI (252-333)	↓	Escherichia coli 53 UI (42-63)	↓
Escherichia coli 432 UI (378-486)	↑	Klebsiella pneumoniae 148 UI (122-174)	↓	Acinetobacter baumannii 33 UI (29-38)	↓
Pseudomonas aeruginosa 241 UI (212-270)	↓	Pseudomonas aeruginosa 129 UI (104-153)	↓	Pseudomonas aeruginosa 33 UI (25-42)	↓
Klebsiella pneumoniae 220 UI (193-247)	↓	Staphylococcus aureus 115 UI (85-145)	↓	Klebsiella pneumoniae 33 UI (26-40)	↓
Streptococcus pneumoniae 169 UI (149-188)	↓	Acinetobacter baumannii 82 UI (71-92)	↓	Staphylococcus aureus 24 UI (20-29)	↓
Enterococcus faecalis 94 UI (83-106)	↓	Streptococcus pneumoniae 75 UI (50-99)	↓	Enterococcus faecium 12 UI (9-15)	↑
Group A Streptococcus 91 UI (78-104)	↑	Enterococcus faecium 64 UI (55-72)	↑	Streptococcus pneumoniae 11 UI (6-15)	↓
Acinetobacter baumannii 83 UI (72-93)	↓	Proteus spp. 45 UI (34-57)	↑	Enterobacter spp. 10 UI (8-12)	↓
Enterobacter spp. 76 UI (67-85)	↓	Enterococcus faecalis 43 UI (36-50)	↑	Enterococcus faecalis 9 UI (7-12)	↑
Proteus spp. 74 UI (64-83)	↑	Enterobacter spp. 41 UI (33-50)	↓	Proteus spp. 6 UI (4-8)	↓

Annualized rate of change (1990-2021): <-3% | -1.5% to 0% | 1.5% to 3% | >5.0% | -3% to -1.5% | 0% to 1.5% | 3% to 5%

Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

Associated			Attributable		
Escherichia coli Aminopenicillin	264 UI (215-312)	↑	Acinetobacter baumannii Carbapenems	19 UI (16-23)	↓
Escherichia coli TMP-SMX	157 UI (121-193)	↓	Pseudomonas aeruginosa Carbapenems	16 UI (10-22)	↓
Escherichia coli Fluoroquinolones	138 UI (107-169)	↑	Staphylococcus aureus Methicillin	12 UI (7-18)	↓
Escherichia coli Beta-Lactam/Lactamase Inhib.	133 UI (104-161)	↓	Escherichia coli Aminopenicillin	12 UI (7-16)	↑
Klebsiella pneumoniae Aminoglycosides	117 UI (94-140)	↓	Escherichia coli Fluoroquinolones	10 UI (5-14)	↑
Klebsiella pneumoniae Beta-Lactam/Lactamase Inhib.	107 UI (79-135)	↓	Escherichia coli Beta-Lactam/Lactamase Inhib.	9 UI (2-17)	↑
Klebsiella pneumoniae Fluoroquinolones	104 UI (83-124)	↓	Klebsiella pneumoniae Aminoglycosides	9 UI (7-12)	↓
Klebsiella pneumoniae TMP-SMX	96 UI (75-118)	↓	Acinetobacter baumannii Fluoroquinolones	9 UI (7-10)	↓
Pseudomonas aeruginosa Carbapenems	85 UI (68-102)	↓	Escherichia coli TMP-SMX	9 UI (5-12)	↓
Acinetobacter baumannii Carbapenems	81 UI (70-91)	↓	Klebsiella pneumoniae Fluoroquinolones	8 UI (5-11)	↑

Annualized rate of change (1990-2021): <-3% | -1.5% to 0% | 1.5% to 3% | >5.0% | -3% to -1.5% | 0% to 1.5% | 3% to 5%

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) bloodstream infections (1,320 UI (1,160-1,480)), lower respiratory infection (excl. COVID) (790 UI (680-900)), peritoneal and intra-abdominal infections (435 UI (379-491)), urinary tract infections and pyelonephritis (273 UI (218-328)) and infections of the skin and subcutaneous systems (193 UI (159-227)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection

Deaths by age group ■ 70+ ■ 50 to 69 ■ 15 to 49 ■ 5 to 14 ■ under 5
The length of each bar represents the number of deaths associated with AMR by age group

- In Latvia, people aged 70+ saw the largest number of deaths associated with AMR both in 1990 and 2021, which indicates that 70+ continues to be particularly vulnerable to infections which are resistant to antibiotics. In 2021, the number of deaths associated with AMR among the 70+ was 722 UI (594-850), whereas the mortality rate per 100,000 was 256 UI (211-302).

Data sources for Latvia

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Latvia by source type

Source type	Years	Sample size	Sample size units
Microbial or laboratory data without outcome	1990-2021	152,209	Isolates
Microbial or laboratory data with outcome	1990-2021	60,118	Isolates
Literature studies	1990-2021	193	Cases/isolates/susceptibility tests
Single drug resistance profile data	1990-2021	91,401	Antibiotic susceptibility test

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care's Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit https://www.healthdata.org/antimicrobial-resistance.

To look at these and more visualization interactively visit Measuring Infectious Causes and Resistance Outcomes for Burden Estimation (MICROBE).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the Global Health Data Exchange (GHDx).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org

- For media-related inquiries: media@healthdata.org

- **Bluesky**: @ihmeuw.bsky.social

- **Twitter**: @IHME_UW

- **Facebook**: https://www.facebook.com/IHMEUW

- **LinkedIn**: https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation